Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTER: Alternating Sacituzumab-govitecan and Trastuzumab-deruxtecan in HER2-low mTNBC
NCT07151586Phase 2Not yet recruiting
- Sponsor
- Unicancer
- Start
- Sep 2026
- Primary completion
- Oct 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab deruxtecan in triple-negative breast cancer (TNBC), sponsored by Unicancer. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07151586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07151586.